D2M Biotherapeutics DM919 Investigational New Drug Application Approved by China’s National Medical Products Administration
Natick, Mass., April 1st, 2024 — D2M Biotherapeutics Inc (D2M), a clinical stage biotech company focused on developing innovative therapies […]
